Article Versions Notes

Takada R, Ikezawa K, Daiku K, Maeda S, Abe Y, Urabe M, Kai Y, Yamai T, Fukutake N, Nakabori T, et al. The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer. Cancers. 2021; 13(18):4733. https://doi.org/10.3390/cancers13184733

Takada, Ryoji, Kenji Ikezawa, Kazuma Daiku, Shingo Maeda, Yutaro Abe, Makiko Urabe, Yugo Kai, Takuo Yamai, Nobuyasu Fukutake, Tasuku Nakabori, and et al. 2021. "The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer" Cancers 13, no. 18: 4733. https://doi.org/10.3390/cancers13184733

Takada, R., Ikezawa, K., Daiku, K., Maeda, S., Abe, Y., Urabe, M., Kai, Y., Yamai, T., Fukutake, N., Nakabori, T., Uehara, H., Ashida, R., Akita, H., Takahashi, H., Teshima, T., & Ohkawa, K. (2021). The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer. Cancers, 13(18), 4733. https://doi.org/10.3390/cancers13184733